Recent news on Polifeprosan 20 With Carmustine Implant

MGI Pharma to Present at the Bank of America Healthcare Conference  -  May 24, 2007
PharmaLive.com (press release),...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA Reports First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $9.7 million for the first quarter of 2007, compared to $9.7 million in the first

Data from Investigator-Sponsored Trial of Oncophage(R) Cancer ...  -  Apr 16, 2007
PipelineReview.com (press release),Dr. Brem is a developer of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma.

MGI Pharma First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
PharmaLive.com (press release),...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
Business Wire (press release),...hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA Announces Positive Results from a Pivotal Phase 3 Study ...  -  Mar 21, 2007
PipelineReview.com (press release),...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

News For Your Web Site  -  Mar 15, 2007
dBusinessNews Minneapolis (press release),...hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States.

Rebecca Dop Completes Certified Trade Show Marketer (CTSM) Program  -  Mar 21, 2007
Exhibitor Online,Aloxi® (palonosetron hydrochloride) Injection, Dacogen ™ (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the US.

MGI Pharma to Present at the 2007 Merrill Lynch Global ...  -  Feb 1, 2007
PharmaLive.com (press release),...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA to Present at the 2007 Merrill Lynch Global ...  -  Jan 31, 2007
dBusinessNews Minneapolis (press release),...hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 8, 2007
PharmaLive.com (press release),...launch of Dacogen(R) (decitabine) for Injection and incorporation of a full year of sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant).

MGI Pharma Announces Publication of Phase 3 Data for Saforis ...  -  18 Jan 2007
PharmaLive.com (press release),...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA Announces Publication of Phase 2 Data Describing ...  -  Jan 3, 2007
Business Wire (press release),...hydrochloride) Injection, Dacogen™ (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 15, 2006
PipelineReview.com (press release),...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 14, 2006
Business Wire (press release),...hydrochloride) Injection, Dacogen™ (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States.

MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the ... -Business Wire (press release), MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the ... -Genetic Engineering News (press release), MGI PHARMA Reports Third Quarter 2006 Financial Results  Oct 18, 2006
...launch of Dacogen™ (decitabine) for Injection, and the inclusion of sales of Gliadel® Wafer (polifeprosan 20 with carmustine implant) following the 2005 ... -Business Wire (press release), GLIADEL IMPLANT'S SURVIVAL BENEFITS TO BE FEATURED AT THE EUROPEAN ...  Sep 14, 2006
Gliadel Implant (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ... -ITNews

MGI PHARMA to Present at the UBS Global Life Sciences Conference  Sep 19, 2006
Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the ... -Business Wire

Carmustine Wafer Implant Clinical Data Presented at Society for ...  -  Nov 20, 2006
DG News...and acute care, today summarized interim results from a phase 2 combination study of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in patients ...

Gliadel(R) Wafer Clinical Data Presented at Society for Neuro ...  -  Nov 20, 2006
Earthtimes.orgGliadel Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ...

Market Report -- In Play (MOGN)  -  Nov 20, 2006
MSN Money...and temozolomide are used Co summarized interim results from a phase 2 combination study of Gliadel Wafer (polifeprosan 20 with carmustine implant) in patients ...

MGI PHARMA (MOGN) Updates Phase 2 Interim Results from Study of ...  -  Nov 20, 2006
StreetInsider.com (subscription),...(Nasdaq: MOGN) summarized interim results from a phase 2 combination study of Gliadel Wafer (polifeprosan 20 with carmustine implant) in patients with newly ...

MGI Pharma to Present at the Lazard Capital Markets Third Annual ...  -  Nov 21, 2006
PharmaLive.com (press release),Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the ...

MGI PHARMA to Present at the Lazard Capital Markets Third Annual ...  -  Nov 20, 2006
Business Wire (press release),Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the ...

Dacogen (Decitabine) For Injection Receives European Orphan Drug ...  Aug 1, 2006
Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the ... -PharmaLive.com

MGI PHARMA Reports Second Quarter 2006 Financial Results  Jul 19, 2006
...sales of Aloxi(R) (palonosetron hydrochloride) Injection, the inclusion of sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) and Aggrastat(R ... -Business Wire

MGI PHARMA Reports Second Quarter 2006 Financial Results  Jul 19, 2006
...sales of Aloxi(R) (palonosetronhydrochloride) Injection, the inclusion of sales of Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) and Aggrastat(R ... -Finanzen.net

MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25 ...  Jul 19, 2006
Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the ... -Business Wire

MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson ...  Jul 6, 2006
Aloxi(R) (palonosetron hydrochloride) Injection,Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) in the ... -Finanzen.net



MGI PHARMA to Present at the 2006 Bank of America Health Care ...  May 11, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Business Wire

Dacogen(TM) Approved For Patients With All FAB Classifications Of ...  May 5, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States, and ... - Medical News Today

MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ...  Apr 18, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com

MGI PHARMA Reports First Quarter 2006 Financial Results; First ...  Apr 19, 2006
Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) totaled $9.7 million for the first quarter of 2006 compared to $7.3 million for the first ... - Business Wire





Gliadel Wafer Demonstrates Long-Term Survival Benefit for Patients ...  Mar 8, 2006
Gliadel Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ... - AScribe

MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal ...  Mar 20, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Business Wire



CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  Feb 9, 2006
2004. Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $8.5 million for the fourth quarter of 2005. Total ... - Genetic Engineering News,

MGI PHARMA Reports Fourth Quarter and Full Year 2005 Financial ...  Feb 8, 2006
2004. Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $8.5 million for the fourth quarter of 2005. Total ... - Genetic Engineering News

MGI PHARMA to Present at the BIO CEO and Investor Conference  Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional